Homepage Bottom Left
-
Health Canada approves Altuviiio
MONTRÉAL, March 31, 2025 – Health Canada has granted marketing approval to Altuviiio (efanesoctocog alfa) for the treatment of hemophilia A in children, adolescents and...
-
Hemgenix 4-year results show steady durability
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...
-
Development halts in first-generation gene therapies
MONTREAL, February 25, 2025 – On February 20, Pfizer announced that it was stopping development of its hemophilia B gene therapy, Beqvez. It cited “soft...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2025 ISSUE ONE of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
-
Now accepting applications for the James Kreppner Scholarship and Bursary Program
The competition for the James Kreppner Memorial Scholarship and Bursary Program is now open. DEADLINE TO APPLY: APRIL 30, 2025 CLICK HERE for all the details.